SILVA, K. S. P. S.; http://lattes.cnpq.br/6327035739299339; SILVA, Karla Sunally Pereira de Sousa.
Resumen:
Dyslipidemias can be defined as changes in circulating lipid levels, characterizing any change
involving lipid metabolism and stand out among the risk factors for atherosclerotic disease.
The indications for individuals with alterations in lipid metabolism include nonpharmacological
and pharmacological interventions. The non-drug treatment basically
involves changes in lifestyle. The hypolipidemic pharmacotherapy presents a well-defined in
combating morbidity and mortality from coronary heart disease role. This study aimed to
review the literature on the pharmacotherapy of dyslipidemia seeking to update the
information to health professionals. Classes of drugs currently used in the treatment are the
statins, fibrates, bile acid sequestrants, ezetimibe, niacin and omega-3. Statins inhibit the ratelimiting
step in cholesterol synthesis and are the preferred drugs hypercholesterolemia.
Fibrates are considered drugs of choice for hypertriglyceridemia. Bile acid sequestrants and
ezetimibe are generally used in combination with other lipid lowering drugs for the treatment
of hypercholesterolemia. Niacin favorably modifies all major lipid fractions and the most
effective drug in elevated levels of HDL-C. The omega-3 reduces serum triglycerides levels.
However, like all drugs, are not without adverse effects. Although transient, as in most cases,
require attention and early detection, as most often become the cause of non-adherence to
treatment. Therefore updated by health professionals about pharmacotherapy, knowledge
plays an important role in the improvement of treatment adherence and management of
dyslipidemia and consequent its complications reduction.